O-21 SOLUBLE CD163 PERFORMANCE AS A NON-INVASIVE BIOMARKER OF DIFFERENT LIVER CONDITIONS

Abstract

Development of noninvasive tests to predict liver injury represents a current goal. Soluble CD163 (sCD163) is a specific plasma biomarker of macrophage activation with promising clinical relevance in estimating damage severity and predicting the outcome in different liver conditions. To evaluate sCD163 performance as a non-invasive marker of liver damage. sCD163 was quantified by enzyme-linked-immunosorbent assay in plasma from 123 patients (57 HCV, 20 HCV/HIV, 10 HBV, 36 MAFLD) obtained at time of liver biopsy. 20 healthy donors were included as controls. sCD163 values were compared among disease conditions and related to histological parameters of liver damage. Diagnostic performance was assessed by the area under the receiver operating characteristic curves (AUROC). Patients´ sCD163 levels [0.579g/L (0.034 -3.596)] were higher than controls´ [0.221g/L (0.116-0.549)] (p<0.0001, Mann-Whitney). However, in a detailed analysis according to disease etiology, only viral conditions showed significantly higher sCD163 levels [HCV+ 0.7520g/L (0.168-3.468), p<0.0001; HCV+/HIV+ 0.964g/L (0.345-3.596), p<0.0001; HBV+ 0.526g/L (0.199-0.802), p=0.0375, Dunn's-multiple-comparisons]. MAFLD patients displayed similar sCD163 levels to the control group [0.345g/L (0.0338-1.804)]. HCV mono- and HIV-coinfected patients shared the highest sCD163 levels. In relation to liver injury, HCV+ and HCV+/HIV+ patients specifically displayed a profile with higher sCD163 levels associated with more severe hepatitis. Remarkably, just in HCV+/HIV+ cases these differences were significant (p=0.0097 Mann-Whitney) and the AUROC analysis demonstrated a good performance in predicting hepatitis severity [AUROC=0.875; cutoff: 0.672g/L (91.67% sensitivity, 83.33% specificity)]. Concerning fibrosis, only HCV+ and HCV+/HIV+ patients with significant fibrosis displayed a profile with high sCD163 level; however, the AUROC analysis showed good performance just for HCV+/HIV+ patients [AUROC=0.825); cutoff: 0.9640g/L (100% sensitivity, 60% specificity)]. Plasmatic sCD163 is elevated in patients with several liver conditions but it can be particularly used as a marker of liver inflammation and fibrosis in HCV/HIV co-infected patients.